Selective Neuronal Vulnerability in Alzheimer's Disease: A Modern Holy Grail

Jessica Rexach; Daniel Geschwind

doi:10.1016/j.neuron.2020.08.018

Selective Neuronal Vulnerability in Alzheimer's Disease: A Modern Holy Grail

Neuron. 2020 Sep 9;107(5):763-765. doi: 10.1016/j.neuron.2020.08.018.

Authors

Jessica Rexach¹, Daniel Geschwind²

Affiliations

¹ Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
² Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: dhg@mednet.ucla.edu.

PMID: 32910887
DOI: 10.1016/j.neuron.2020.08.018

Abstract

In this issue of Neuron, through an elegant progression of computational and bio-informatic experiments centered on transcriptomic comparison of vulnerable and resistant neurons across species, Roussarie et al. (2020) predict and provide experimental support for specific genes and molecular pathways driving Alzheimer's disease, including the splicing factor PTBP1.

Publication types

Comment

MeSH terms

Alzheimer Disease* / genetics
Heterogeneous-Nuclear Ribonucleoproteins
Humans
Neurons
Polypyrimidine Tract-Binding Protein

Substances

Heterogeneous-Nuclear Ribonucleoproteins
PTBP1 protein, human
Polypyrimidine Tract-Binding Protein